Quantcast
Get breaking news alerts via email

Click here to manage your alerts
AP file photo “We believe that [suppliers] will be able to meet the demands of patients in the U.S. market” for the two drugs indefinitely, said FDA Commissioner Dr. Margaret Hamburg.
FDA eases shortages of cancer drugs
Health » Officials say short-term fix won’t solve long-term problem.
First Published Feb 21 2012 05:42 pm • Last Updated Feb 21 2012 10:18 pm

Federal regulators have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been ratcheting up fears that patients, particularly children with leukemia, would miss lifesaving treatments.

But there are 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to give patients and doctors nightmares.

Join the Discussion
Post a Comment

On Tuesday, the Food and Drug Administration said it will temporarily allow importation of a replacement drug for Doxil, a drug for recurrent ovarian or bone marrow cancer. The Johnson & Johnson drug hasn’t been available for new patients for months because J&J’s contract manufacturer had to shut down production over serious quality lapses.

The FDA also has approved a new supplier for a preservative-free version of methotrexate, a crucial drug for children with a type of leukemia called ALL, for lymphomas and for the bone cancer osteosarcoma. The version with preservatives, the one that’s been scarce, can be toxic or cause paralysis in children and other patients getting the drug either by injections into spinal cord fluid or at very high doses.

The FDA also has approved the release of a batch manufactured by Ben Venue Laboratories Inc., shortly before it closed several factories at its complex in Bedford, Ohio, due to serious quality problems. That closing was what turned the periodic methotrexate shortage that began in late 2008 into a crisis almost overnight, with fears that kids would begin missing treatments within weeks.

"We believe that (suppliers) will be able to meet the demands of patients in the U.S. market" for the two drugs indefinitely, said FDA Commissioner Dr. Margaret Hamburg.

Numerous medical and drugmaker groups, along with the White House, applauded the news but cautioned that much still must be done to resolve all the problems causing shortages.

The FDA increasingly has been able to prevent shortages, mainly due to a sixfold increase in manufacturers voluntarily notifying the FDA when they anticipate shortages and agency efforts to expedite any approvals needed for new production lines, Hamburg said.

Thanks to such notice, the agency prevented 195 drug shortages in 2011, mostly late in the year after President Obama issued an executive order giving FDA additional resources to address the shortages. Hamburg said companies have been "very responsive" when FDA asks them to boost production after another company warns it will halt a drug’s production.

In the latest case, the FDA has temporarily allowed importation of an alternative to Doxil called Lipodox, made by Sun Pharma Global FZE. The Indian drugmaker already sells products in the U.S., and its factory has been inspected.


story continues below
story continues below

The FDA is allowing APP Pharmaceuticals LLC to make the preservative-free version of methotrexate in addition to its current drug with preservatives. The company had made a preservative-free version years ago, but needed to update paperwork and meet other requirements, which the FDA expedited.

"Within the next four to six weeks, we can supply clinics with this drug," Mitchell L. Ehrlich, a vice president with APP parent Fresenius Kabi USA, said during a Washington news conference announcing the new steps.

Ehrlich said his company previously helped resolve serious shortages of other important drugs, such as by increasing production of doxorubicin — which treats several types of cancer — from 10 percent of the market supply to 60 percent.

Hospira Inc. on Monday began shipping 31,000 vials of preservative-free methotrexate, more than enough to meet a month’s U.S. demand, to hundreds of hospitals and treatment centers, said its CEO, Mike Ball. He said the company will ship another 34,000 units next week and 55,000 more in mid-March to build a supply cushion. It’s also now transporting from around the world to its Australian factory about 100 kilograms of methotrexate’s active ingredient — enough to make about a three- to four-month supply.

Two other companies, Mylan Inc. and Sandoz Inc., also are ramping up their production of preservative-free methotrexate.

Still, hundreds of other drugs remain in short supply, including at least six for cancer.

"I don’t think we can ever close the book on drug shortages," Hamburg told The AP. "I think we will always have to be vigilant."

Drug shortages have increased dramatically in the U.S. over the past six years, particularly for generic injected drugs. They are the workhorses of hospitals but are difficult to make and produce little profit for drugmakers. At least 15 deaths since 2010 have been blamed on the shortages.

Doctors have had to resort to second-choice drugs that don’t work nearly as well, have more-serious side effects or cost much more than one unavailable. For some drugs, there simply isn’t a good alternative.

So far this year, 27 new shortages have been reported, and about 215 that began in 2010 or 2011 remain unresolved, according to Erin R. Fox, manager of the University of Utah Drug Information Service, which tracks shortages.

"At this time last year, we were on a pace of about one new shortage per day. Thanks to FDA’s hard work, that pace is cut in half for this first part of 2012," Fox said.

Next Page >


Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.